Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
EXELIXIS INC (1EXEL.MI) Stock Price & Overview
BIT:1EXEL • US30161Q1040
Current stock price
37.515 EUR
+6.82 (+22.2%)
Last:
The current stock price of 1EXEL.MI is 37.515 EUR. Today 1EXEL.MI is up by 22.2%.
1EXEL.MI Key Statistics
- Market Cap
- 9.743B
- P/E
- 15.96
- Fwd P/E
- 13.85
- EPS (TTM)
- 2.35
- Dividend Yield
- N/A
1EXEL.MI Stock Performance
Today
+22.2%
1 Week
+4.32%
1 Month
N/A
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
1EXEL.MI Stock Chart
1EXEL.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1EXEL.MI.
Chartmill TA Rating
Chartmill Setup Rating
1EXEL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to 1EXEL.MI. Both the health and profitability get an excellent rating, making 1EXEL.MI a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
1EXEL.MI Earnings
On February 10, 2026 1EXEL.MI reported an EPS of 0.88 and a revenue of 598.66M. The company beat EPS expectations (7.04% surprise) and missed revenue expectations (-2.85% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 10, 2026
PeriodQ4 / 2025
EPS Reported$0.88
Revenue Reported598.663M
EPS Surprise 7.04%
Revenue Surprise -2.85%
1EXEL.MI Forecast & Estimates
27 analysts have analysed 1EXEL.MI and the average price target is 39.8 EUR. This implies a price increase of 6.09% is expected in the next year compared to the current price of 37.515.
For the next year, analysts expect an EPS growth of 15.38% and a revenue growth 11.08% for 1EXEL.MI
Analysts
Analysts74.81
Price Target39.8 (6.09%)
EPS Next Y15.38%
Revenue Next Year11.08%
1EXEL.MI Financial Highlights
Over the last trailing twelve months 1EXEL.MI reported a non-GAAP Earnings per Share(EPS) of 2.35. The EPS increased by 49.73% compared to the year before.
Income Statements
Revenue(TTM)2.32B
Net Income(TTM)782.57M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.73% | ||
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%83.33%
Sales Q2Q%5.63%
EPS 1Y (TTM)49.73%
Revenue 1Y (TTM)6.98%
1EXEL.MI Ownership
Ownership
Inst Owners102.79%
Shares259.71M
Float253.59M
Ins Owners2.35%
Short Float %N/A
Short RatioN/A
1EXEL.MI Industry Overview
1EXEL.MI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
1EXEL.MI Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.81 | 41.543B | ||
| 1AE | ARGENX SE | 28.79 | 41.518B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.443B | ||
| ABVX | ABIVAX SA | N/A | 7.648B | ||
| 2X1 | ABIVAX SA | N/A | 7.64B | ||
| GLPG | GALAPAGOS NV | N/A | 1.591B | ||
| GXE | GALAPAGOS NV | N/A | 1.59B | ||
| NANO | NANOBIOTIX | N/A | 1.39B | ||
| PHARM | PHARMING GROUP NV | 47.29 | 1.011B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.01B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.008B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 895.23M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1EXEL.MI
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
IPO: 2000-04-11
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA US
Employees: 1077
Phone: 13026587581
EXELIXIS INC / 1EXEL.MI FAQ
Can you describe the business of EXELIXIS INC?
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
What is the stock price of EXELIXIS INC today?
The current stock price of 1EXEL.MI is 37.515 EUR. The price increased by 22.2% in the last trading session.
What is the dividend status of EXELIXIS INC?
1EXEL.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1EXEL stock?
1EXEL.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
Where is EXELIXIS INC (1EXEL.MI) stock traded?
1EXEL.MI stock is listed on the Euronext Milan exchange.
What is the analyst forecast for 1EXEL.MI stock?
27 analysts have analysed 1EXEL.MI and the average price target is 39.8 EUR. This implies a price increase of 6.09% is expected in the next year compared to the current price of 37.515.
Can you provide the ownership details for 1EXEL stock?
You can find the ownership structure of EXELIXIS INC (1EXEL.MI) on the Ownership tab.